secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2024-12-27T23:59:59+00:00
Accession:  0001104659-24-132132
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ReShape Lifesciences enters up to $5M equity purchase agreement with investor
-----------------------------------------------------------------------------

- Equity purchase agreement for up to $5M over 36 months; pricing at 93% of prior-day VWAP with a true-up mechanism.
- Investor receives 17,300 shares and pre-funded warrant for 21,015 shares as commitment fee; short selling prohibited.
- Issuance capped at 19.9% of outstanding shares unless stockholder approval or price exceeds Nasdaq Official Closing Price thresholds.
- Proceeds expected for working capital and merger with Vyome Therapeutics; 66% of net proceeds must prepay existing convertible note.
- Company filed S-1 to register resale of shares; agreement may be terminated by Company on 5 days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000110465924132132/0001104659-24-132132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000110465924132132/tm2431533d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-132132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer